Arcus Biosciences
RCUS
190 hedge funds and large institutions have $1.37B invested in Arcus Biosciences in 2025 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 65 increasing their positions, 61 reducing their positions, and 24 closing their positions.
2,013% more call options, than puts
Call options by funds: $46.2M | Put options by funds: $2.19M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
69% more capital invested
Capital invested by funds: $811M → $1.37B (+$557M)
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
3% more funds holding
Funds holding: 185 → 190 (+5)
7% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 61
0.36% more ownership
Funds ownership: 94.18% → 94.53% (+0.36%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$13.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$8.97M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$6.66M |
| 4 |
DC
Decheng Capital
Menlo Park,
California
|
+$4.03M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.29M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.88M |
| 4 |
Jane Street
New York
|
-$2.67M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.45M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Nomura Holdings
Tokyo,
Japan
| – | -$162K | -15,603 | Closed |
|
|
EGM
202
Engineers Gate Manager
New York
| – | -$110K | -13,540 | Closed |
|
|
DS
203
DRW Securities
Chicago,
Illinois
| – | -$108K | -13,285 | Closed |
|
|
PD
204
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$104K | -12,796 | Closed |
|
205
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$92K | -11,304 | Closed |
|
206
PEAK6
Chicago,
Illinois
| – | -$81.4K | -10,000 | Closed |
|
|
PHK
207
Point72 Hong Kong
Hong Kong
| – | -$65K | -7,991 | Closed |
|
|
CIAM
208
Caitong International Asset Management
Hong Kong
| – | -$3.39K | -417 | Closed |
|
|
BIG
209
Brooklyn Investment Group
Brooklyn,
New York
| – | -$2.95K | -362 | Closed |
|
|
MCM
210
MAI Capital Management
Independence,
Ohio
| – | -$1.97K | -242 | Closed |
|
|
C
211
Covestor
London,
United Kingdom
| – | -$1.87K | -180 | -96% |
|
|
FFO
212
Fortitude Family Office
Scottsdale,
Arizona
| – | -$488 | -60 | Closed |
|
RCUS Hedge Fund Activity: Q3 2025 in Review
190 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2025, worth a combined $1.37B — up 69% from $811M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RCUS positions and 24 closed out — a net gain of 6 holders — while 65 added to existing stakes and 61 trimmed.
The largest buyer was Siren LLC, adding an estimated $13.5M. The largest seller was Point72 Asset Management, cutting an estimated $17M.
- 190 institutional investors held Arcus Biosciences (RCUS) as of Q3 2025, up from 185 in Q2 2025.
- Funds reported $1.37B of Arcus Biosciences stock for Q3 2025, up 69% quarter-over-quarter.
- 30 funds opened new Arcus Biosciences positions in Q3 2025 and 24 closed out, a net change of +6 holders.
- The largest Arcus Biosciences buyer in Q3 2025 was Siren LLC, an estimated $13.5M added.
- The largest Arcus Biosciences seller in Q3 2025 was Point72 Asset Management, an estimated $17M sold.
Based on aggregated 13F filings for Q3 2025.